Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation

Journal of Clinical Oncology, Vol 15, 594-603, Copyright © 1997 by American Society of Clinical Oncology

ARTICLES

International Germ Cell Consensus Classification: a prognostic factor- based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group


PURPOSE: Cisplatin-containing chemotherapy has dramatically improved the outlook for patients with metastatic germ cell tumors (GCT), and overall cure rates now exceed 80%. To make appropriate risk-based decisions about therapy and to facilitate collaborative trials, a simple prognostic factor-based staging classification is required. MATERIALS: Collaborative groups from 10 countries provided clinical data on patients with metastatic GCT treated with cisplatin-containing chemotherapy. Multivariate analyses of prognostic factors for progression and survival were performed and models were validated on an independent data set. RESULTS: Data were available on 5,202 patients with nonseminomatous GCT (NSGCT) and 660 patients with seminoma. Median follow-up time was 5 years. For NSGCT the following independent adverse factors were identified: mediastinal primary site; degree of elevation of alpha-fetoprotein (AFP), human chorionic gonadotropin (HCG), and lactic dehydrogenase (LDH); and presence of nonpulmonary visceral metastases (NPVM), such as liver, bone, and brain. For seminoma, the predominant adverse feature was the presence of NPVM. Integration of these factors produced the following groupings: good prognosis, comprising 60% of GCT with a 91% (89% to 93%) 5-year survival rate; intermediate prognosis, comprising 26% of GCT with a 79% (75% to 83%) 5- year survival rate; and poor prognosis, comprising 14% of GCT (all with NSGCT) with a 48% (42% to 54%) 5-year survival rate. CONCLUSION: An easily applicable, clinically based, prognostic classification for GCT has been agreed on between all the major clinical trial groups who are presently active worldwide. This should be used in clinical practice and in the design and reporting of clinical trials to aid international collaboration and understanding.


This article has been cited by other articles:


Home page
 JCOHome page
G. C. Toner
Clinical Relevance of "Late" in the Management of Late Relapse After Treatment for a Germ Cell Tumor
J. Clin. Oncol., December 1, 2008; 26(34): 5502 - 5503.
[Full Text] [PDF]

Home page
 Clin. Chem.Home page
C. M. Sturgeon, M. J. Duffy, U.-H. Stenman, H. Lilja, N. Brunner, D. W. Chan, R. Babaian, R. C. Bast Jr., B. Dowell, F. J. Esteva, et al.
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers
Clin. Chem., December 1, 2008; 54(12): e11 - e79.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
M. J. Duffy and J. Crown
A Personalized Approach to Cancer Treatment: How Biomarkers Can Help
Clin. Chem., November 1, 2008; 54(11): 1770 - 1779.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
B. E.P.B. Ballieux, N. I. Weijl, H. Gelderblom, J. van Pelt, and S. Osanto
False-Positive Serum Human Chorionic Gonadotropin (hCG) in a Male Patient with a Malignant Germ Cell Tumor of the Testis: A Case Report and Review of the Literature
Oncologist, November 1, 2008; 13(11): 1149 - 1154.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Roentgenol.Home page
S. A. Sohaib, D.-M. Koh, and J. E. Husband
The Role of Imaging in the Diagnosis, Staging, and Management of Testicular Cancer
Am. J. Roentgenol., August 1, 2008; 191(2): 387 - 395.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
M. Inoue, F. Koga, S. Kawakami, N. Numao, M. Sakura, T. Kobayashi, and K. Kihara
False Tumor Marker Surge Evoked by Peripheral Blood Stem Cell Transplantation
Oncologist, May 1, 2008; 13(5): 526 - 529.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. C. de Haas, N. Zwart, C. Meijer, J. Nuver, H. M. Boezen, A. J.H. Suurmeijer, H. J. Hoekstra, G. van der Steege, D. Th. Sleijfer, and J. A. Gietema
Variation in Bleomycin Hydrolase Gene Is Associated With Reduced Survival After Chemotherapy for Testicular Germ Cell Cancer
J. Clin. Oncol., April 10, 2008; 26(11): 1817 - 1823.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
I. Shintaku, M. Satoh, E. Okajima, H. Fujimoto, T. Kamoto, O. Ogawa, K. Kawai, H. Akaza, T. Tsukamoto, S. Naito, et al.
Survival of Metastatic Germ Cell Cancer Patients Assessed by International Germ Cell Consensus Classification in Japan
Jpn. J. Clin. Oncol., April 1, 2008; 38(4): 281 - 287.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. J. Wheater, G. M. Mead, S. Bhandari, and J. Fennell
Recombinant Factor VIIa in the Management of Pulmonary Hemorrhage Associated With Metastatic Choriocarcinoma
J. Clin. Oncol., February 20, 2008; 26(6): 1008 - 1010.
[Full Text] [PDF]

Home page
 JAMAHome page
D. R. Feldman, G. J. Bosl, J. Sheinfeld, and R. J. Motzer
Medical Treatment of Advanced Testicular Cancer
JAMA, February 13, 2008; 299(6): 672 - 684.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
K. A. Kesler, K. M. Rieger, Z. T. Hammoud, L. E. Kruter, S. M. Perkins, M. W. Turrentine, B. P. Schneider, L. H. Einhorn, and J. W. Brown
A 25-Year Single Institution Experience With Surgery for Primary Mediastinal Nonseminomatous Germ Cell Tumors
Ann. Thorac. Surg., February 1, 2008; 85(2): 371 - 378.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
C. H. Kang, Y. T. Kim, S.-H. Jheon, S.-w. Sung, and J. H. Kim
Surgical Treatment of Malignant Mediastinal Nonseminomatous Germ Cell Tumor
Ann. Thorac. Surg., February 1, 2008; 85(2): 379 - 384.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
K. Fizazi, J. Oldenburg, A. Dunant, I. Chen, R. Salvioni, J. T. Hartmann, M. De Santis, G. Daugaard, A. Flechon, U. de Giorgi, et al.
Assessing prognosis and optimizing treatment in patients with postchemotherapy viable nonseminomatous germ-cell tumors (NSGCT): results of the sCR2 international study
Ann. Onc., February 1, 2008; 19(2): 259 - 264.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
R. A. Huddart
The management of non-seminomatous germ-cell tumours patients with viable malignancy at the time of RPLND
Ann. Onc., February 1, 2008; 19(2): 203 - 204.
[Full Text] [PDF]

Home page
 JCOHome page
S. Culine, A. Kramar, C. Theodore, L. Geoffrois, C. Chevreau, P. Biron, B. B. Nguyen, J.-F. Heron, P. Kerbrat, A. Caty, et al.
Randomized Trial Comparing Bleomycin/Etoposide/Cisplatin With Alternating Cisplatin/Cyclophosphamide/Doxorubicin and Vinblastine/Bleomycin Regimens of Chemotherapy for Patients With Intermediate- and Poor-Risk Metastatic Nonseminomatous Germ Cell Tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP
J. Clin. Oncol., January 20, 2008; 26(3): 421 - 427.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
D M Berney
Staging and classification of testicular tumours: pitfalls from macroscopy to diagnosis
J. Clin. Pathol., January 1, 2008; 61(1): 20 - 24.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. T. Hartmann, T. Gauler, B. Metzner, A. Gerl, J. Casper, O. Rick, M. Horger, J. Schleicher, G. Derigs, R. Mayer-Steinacker, et al.
Phase I/II Study of Sequential Dose-Intensified Ifosfamide, Cisplatin, and Etoposide Plus Paclitaxel As Induction Chemotherapy for Poor Prognosis Germ Cell Tumors by the German Testicular Cancer Study Group
J. Clin. Oncol., December 20, 2007; 25(36): 5742 - 5747.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. J. Stephenson, G. J. Bosl, R. J. Motzer, D. F. Bajorin, J. P. Stasi, and J. Sheinfeld
Nonrandomized Comparison of Primary Chemotherapy and Retroperitoneal Lymph Node Dissection for Clinical Stage IIA and IIB Nonseminomatous Germ Cell Testicular Cancer
J. Clin. Oncol., December 10, 2007; 25(35): 5597 - 5602.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
B. S. Carver, A. M. Serio, D. Bajorin, R. J. Motzer, J. Stasi, G. J. Bosl, A. J. Vickers, and J. Sheinfeld
Improved Clinical Outcome in Recent Years for Men With Metastatic Nonseminomatous Germ Cell Tumors
J. Clin. Oncol., December 10, 2007; 25(35): 5603 - 5608.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. F. Bajorin
The Graying of Testis Cancer Patients: What Have We Learned?
J. Clin. Oncol., October 1, 2007; 25(28): 4341 - 4343.
[Full Text] [PDF]

Home page
 JCOHome page
R. de Wit
Refining the Optimal Chemotherapy Regimen in Good Prognosis Germ Cell Cancer: Interpretation of the Current Body of Knowledge
J. Clin. Oncol., October 1, 2007; 25(28): 4346 - 4349.
[Full Text] [PDF]

Home page
 Postgrad. Med. J.Home page
O. Khan and A. Protheroe
Testis cancer
Postgrad. Med. J., October 1, 2007; 83(984): 624 - 632.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
L. H. Einhorn, S. D. Williams, A. Chamness, M. J. Brames, S. M. Perkins, and R. Abonour
High-Dose Chemotherapy and Stem-Cell Rescue for Metastatic Germ-Cell Tumors
N. Engl. J. Med., July 26, 2007; 357(4): 340 - 348.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
S Culine, P Kerbrat, A Kramar, C Theodore, C Chevreau, L Geoffrois, N. Bui, J Peny, A Caty, R Delva, et al.
Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP)
Ann. Onc., May 1, 2007; 18(5): 917 - 924.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. de Wit
Cutting Back on Computed Tomography Scan Frequency in Curative Oncology: Get the Picture
J. Clin. Oncol., April 10, 2007; 25(11): 1308 - 1309.
[Full Text] [PDF]

Home page
 JCOHome page
G. J. Rustin, G. M. Mead, S. P. Stenning, P. A. Vasey, N. Aass, R. A. Huddart, M. P. Sokal, J. K. Joffe, S. J. Harland, and S. J. Kirk
Randomized Trial of Two or Five Computed Tomography Scans in the Surveillance of Patients With Stage I Nonseminomatous Germ Cell Tumors of the Testis: Medical Research Council Trial TE08, ISRCTN56475197--The National Cancer Research Institute Testis Cancer Clinical Studies Group
J. Clin. Oncol., April 10, 2007; 25(11): 1310 - 1315.
[Abstract] [Full Text] [PDF]

Home page
 BrainHome page
A. Krarup-Hansen, S. Helweg-Larsen, H. Schmalbruch, M. Rorth, and C. Krarup
Neuronal involvement in cisplatin neuropathy: prospective clinical and neurophysiological studies
Brain, April 1, 2007; 130(4): 1076 - 1088.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
B. S. Carver, B. Shayegan, A. Serio, R. J. Motzer, G. J. Bosl, and J. Sheinfeld
Long-Term Clinical Outcome After Postchemotherapy Retroperitoneal Lymph Node Dissection in Men With Residual Teratoma
J. Clin. Oncol., March 20, 2007; 25(9): 1033 - 1037.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
K. Ishikawa, A. Sasaki, N. Haraguchi, Y. Yoshikawa, and M. Mori
A Case of an {alpha}-Fetoprotein-Producing Intrahepatic Cholangiocarcinoma Suggests Probable Cancer Stem Cell Origin
Oncologist, March 1, 2007; 12(3): 320 - 324.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
D. S. Kaufman, M. A. Saksena, R. H. Young, and S. Tabatabaei
Case 6-2007 -- A 28-Year-Old Man with a Mass in the Testis
N. Engl. J. Med., February 22, 2007; 356(8): 842 - 849.
[Full Text] [PDF]

Home page
 JCOHome page
D. J. Vaughn and E. A. Stadtmauer
Poor-Prognosis Germ Cell Tumors: We Have Not Yet Crossed the Finish Line
J. Clin. Oncol., January 20, 2007; 25(3): 239 - 240.
[Full Text] [PDF]

Home page
 JCOHome page
R. J. Motzer, C. J. Nichols, K. A. Margolin, J. Bacik, P. G. Richardson, N. J. Vogelzang, D. F. Bajorin, P. N. Lara Jr, L. Einhorn, M. Mazumdar, et al.
Phase III Randomized Trial of Conventional-Dose Chemotherapy With or Without High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Rescue As First-Line Treatment for Patients With Poor-Prognosis Metastatic Germ Cell Tumors
J. Clin. Oncol., January 20, 2007; 25(3): 247 - 256.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
G. Sonpavde, T. E. Hutson, and B. J. Roth
Management of Recurrent Testicular Germ Cell Tumors
Oncologist, January 1, 2007; 12(1): 51 - 61.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. F. Bajorin, R. J. Motzer, and G. J. Bosl
Advances in Urologic Oncology: Results Progress From Successful Interdisciplinary Research
J. Clin. Oncol., December 10, 2006; 24(35): 5479 - 5481.
[Full Text] [PDF]

Home page
 JCOHome page
G. V. Kondagunta and R. J. Motzer
Chemotherapy for Advanced Germ Cell Tumors
J. Clin. Oncol., December 10, 2006; 24(35): 5493 - 5502.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. Oldenburg, J. M. Martin, and S. D. Fossa
Late Relapses of Germ Cell Malignancies: Incidence, Management, and Prognosis
J. Clin. Oncol., December 10, 2006; 24(35): 5503 - 5511.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
K. Kawai, S. Hinotsu, T. Oikawa, N. Sekido, K. Hattori, N. Miyanaga, Y. Hasegawa, H. Kojima, T. Shimazui, and H. Akaza
Treatment Outcome of Metastatic Testicular Cancer at a Single Institution in Japan, a Country with Low Incidence of Germ Cell Tumor
Jpn. J. Clin. Oncol., November 1, 2006; 36(11): 723 - 730.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
N. Murugaesu, P. Schmid, G. Dancey, R. Agarwal, L. Holden, I. McNeish, P. M. Savage, E. S. Newlands, G. J.S. Rustin, and M. J. Seckl
Malignant Ovarian Germ Cell Tumors: Identification of Novel Prognostic Markers and Long-Term Outcome After Multimodality Treatment
J. Clin. Oncol., October 20, 2006; 24(30): 4862 - 4866.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
P Pedrazzoli, J. Ledermann, J-P Lotz, S Leyvraz, M Aglietta, G Rosti, K. Champion, S Secondino, F Selle, N Ketterer, et al.
High dose chemotherapy with autologous hematopoietic stem cell support for solid tumors other than breast cancer in adults
Ann. Onc., October 1, 2006; 17(10): 1479 - 1488.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
K. Kawai, S. Ando, S. Hinotsu, T. Oikawa, N. Sekido, N. Miyanaga, T. Shimazui, and H. Akaza
Completion and Toxicity of Induction Chemotherapy for Metastatic Testicular Cancer: An Updated Evaluation of Japanese Patients
Jpn. J. Clin. Oncol., July 1, 2006; 36(7): 425 - 431.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
N. Marina, W. B. London, A. L. Frazier, S. Lauer, F. Rescorla, B. Cushing, M. H. Malogolowkin, R. P. Castleberry, R. B. Womer, and T. Olson
Prognostic Factors in Children With Extragonadal Malignant Germ Cell Tumors: A Pediatric Intergroup Study
J. Clin. Oncol., June 1, 2006; 24(16): 2544 - 2548.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
L. H. Einhorn and R. S. Foster
Bleomycin, Etoposide, and Cisplatin for Three Cycles Compared With Etoposide and Cisplatin for Four Cycles in Good-Risk Germ Cell Tumors: Is There a Preferred Regimen?
J. Clin. Oncol., June 1, 2006; 24(16): 2597 - 2598.
[Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
T. Tanaka, H. Kitamura, Y. Kunishima, S. Takahashi, A. Takahashi, N. Masumori, N. Itoh, and T. Tsukamoto
Modified and Bilateral Retroperitoneal Lymph Node Dissection for Testicular Cancer: Peri- and Postoperative Complications and Therapeutic Outcome
Jpn. J. Clin. Oncol., June 1, 2006; 36(6): 381 - 386.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. V. Kondagunta, J. Bacik, D. Bajorin, D. Dobrzynski, J. Sheinfeld, R. J. Motzer, and G. J. Bosl
Etoposide and Cisplatin Chemotherapy for Metastatic Good-Risk Germ Cell Tumors
J. Clin. Oncol., December 20, 2005; 23(36): 9290 - 9294.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
B. S. Carver and J. Sheinfeld
Germ Cell Tumors of the Testis
Ann. Surg. Oncol., November 1, 2005; 12(11): 871 - 880.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
B. V. Duwe, D. H. Sterman, and A. I. Musani
Tumors of the Mediastinum
Chest, October 1, 2005; 128(4): 2893 - 2909.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J.-L. Pico, G. Rosti, A. Kramar, H. Wandt, V. Koza, R. Salvioni, C. Theodore, G. Lelli, W. Siegert, A. Horwich, et al.
A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours
Ann. Onc., July 1, 2005; 16(7): 1152 - 1159.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
U. De Giorgi, T. Demirer, H. Wandt, C. Taverna, W. Siegert, M. Bornhauser, T. Kozak, G. Papiani, M. Ballardini, G. Rosti, et al.
Second-line high-dose chemotherapy in patients with mediastinal and retroperitoneal primary non-seminomatous germ cell tumors: the EBMT experience
Ann. Onc., January 1, 2005; 16(1): 146 - 151.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
K. Fizazi, S. Culine, A. Kramar, R. J. Amato, J. Bouzy, I. Chen, J.-P. Droz, and C. J. Logothetis
Early Predicted Time to Normalization of Tumor Markers Predicts Outcome in Poor-Prognosis Nonseminomatous Germ Cell Tumors
J. Clin. Oncol., October 1, 2004; 22(19): 3868 - 3876.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. C. Toner
Early Identification of Therapeutic Failure in Nonseminomatous Germ Cell Tumors by Assessing Serum Tumor Marker Decline During Chemotherapy: Still Not Ready for Routine Clinical Use
J. Clin. Oncol., October 1, 2004; 22(19): 3842 - 3845.
[Full Text] [PDF]

Home page
 Ann OncolHome page
H. J. Schmoll, R. Souchon, S. Krege, P. Albers, J. Beyer, C. Kollmannsberger, S. D. Fossa, N. E. Skakkebaek, R. de Wit, K. Fizazi, et al.
European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG)
Ann. Onc., September 1, 2004; 15(9): 1377 - 1399.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M. R. van Dijk, E. W. Steyerberg, S. P. Stenning, and J. D. F. Habbema
Identifying subgroups among poor prognosis patients with nonseminomatous germ cell cancer by tree modelling: a validation study
Ann. Onc., September 1, 2004; 15(9): 1400 - 1405.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
H. Sakurai, H. Asamura, K. Suzuki, S.-i. Watanabe, and R. Tsuchiya
Management of Primary Malignant Germ Cell Tumor of the Mediastinum
Jpn. J. Clin. Oncol., July 1, 2004; 34(7): 386 - 392.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. F. V. Woude, G. J. Kelloff, R. W. Ruddon, H.-M. Koo, C. C. Sigman, J. C. Barrett, R. W. Day, A. P. Dicker, R. S. Kerbel, D. R. Parkinson, et al.
Reanalysis of Cancer Drugs: Old Drugs, New Tricks
Clin. Cancer Res., June 1, 2004; 10(11): 3897 - 3907.
[Full Text] [PDF]

Home page
 JCOHome page
H. Nakajima, M. Oki, S. Matsukura, M. Nakamura, M. Tokunaga, and K. Ando
Germ Cell Tumors: CASE 1. Intraocular Metastases From Testicular Cancer
J. Clin. Oncol., May 1, 2004; 22(9): 1753 - 1755.
[Full Text] [PDF]

Home page
 JCOHome page
D. Gholam, J.-P. Lotz, D. Atallah, and C. Theodore
Germ Cell Tumors: CASE 2. Unusual Course of Pure Testicular Seminoma
J. Clin. Oncol., May 1, 2004; 22(9): 1755 - 1756.
[Full Text] [PDF]

Home page
 JCOHome page
B. P. Schneider, K. A. Kesler, J. A. Brooks, C. Yiannoutsos, and L. H. Einhorn
Outcome of Patients With Residual Germ Cell or Non-Germ Cell Malignancy After Resection of Primary Mediastinal Nonseminomatous Germ Cell Cancer
J. Clin. Oncol., April 1, 2004; 22(7): 1195 - 1200.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
M. J. Duffy, C. Duggan, R. Keane, A. D.K. Hill, E. McDermott, J. Crown, and N. O'Higgins
High Preoperative CA 15-3 Concentrations Predict Adverse Outcome in Node-Negative and Node-Positive Breast Cancer: Study of 600 Patients with Histologically Confirmed Breast Cancer
Clin. Chem., March 1, 2004; 50(3): 559 - 563.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. Bajorin
The Phase III Candidate: Can We Improve the Science of Selection?
J. Clin. Oncol., January 15, 2004; 22(2): 211 - 213.
[Full Text] [PDF]